Two-phase subcutaneous administration regimen of anti-VLA-4 antibody

JP2023549816A5Pending Publication Date: 2024-11-19BIOGEN MA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528433
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-01-28
Filing Date
2021-11-12
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The pharmacokinetic profiles of biotherapeutics differ significantly between intravenous (IV) and subcutaneous (SC) administration, leading to incomplete bioavailability and the need for higher SC dosages to achieve therapeutically effective concentrations, with SC administration posing risks like progressive multifocal leukoencephalopathy (PML) due to varying pharmacodynamics.

Method used

A two-phase dosing regimen involving a standard interval dosing (SID) induction phase followed by an extended interval dosing (EID) chronic phase, primarily using subcutaneous administration, to maintain therapeutic efficacy and reduce PML risk, with consistent dosing between IV and SC routes.

Benefits of technology

This regimen ensures similar natalizumab trough concentrations and α-4 integrin saturation, improving safety and patient compliance while reducing PML risk without compromising efficacy, facilitating convenient SC administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein is a two-phase dosing protocol for natalizumab treatment that includes both standard and extended interval dosing, as well as subcutaneous administration.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims the benefit of U.S. Provisional Patent Application No. 63 / 113,864, filed November 14, 2020, and U.S. Provisional Patent Application No. 63 / 142,968, filed January 28, 2021, each of which is incorporated by reference herein for all purposes. [Background technology]

[0002] Subcutaneous (SC) administration of biotherapeutics is an important alternative to intravenous (IV) administration and can significantly reduce patient treatment burden, including reduced hospital time, increased comfort during administration, reduced psychological distress during treatment, and decreased pain at the injection site (Rummel et al., Ann. Oncol. 2017;28(4):836-842). Furthermore, the convenience and speed of SC administration translates into time and cost savings for the healthcare system, reducing the burden on infusion centers and increasing patient access (Dychter et al., J. Infus Nurs. 2012;35(3):154-160).

[0003] Unfortunately, however, the pharmacokinetic profiles between the two routes of administration can differ significantly (Bittner et al., Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs, 32:425-440, 2018). Intravenous administration of biotherapeutics results in almost immediate maximum serum concentrations (C max ), whereas SC administration is usually absorbed slowly and results in a significantly lower C than that obtained with IV administration. max(ibid., p. 432). This is the result of limited permeability of biotherapeutics across the vascular endothelium, as well as interactions with interstitial glycosaminoglycans and proteins and enzymatic degradation. Therefore, incomplete bioavailability is a characteristic of SC administration compared with IV administration, and increased SC doses are often required to achieve comparable therapeutic concentrations. Because the pharmacodynamics and pharmacokinetics between the two routes of administration are different and specific to individual biotherapeutics (ibid., p. 436), caution and uncertainty remain regarding the use of SC administration for biotherapeutics traditionally administered via IV administration. As a more recent example, Cinquair® (reslizumab) is an approved IV treatment for asthma, but has failed as a fixed-dose subcutaneous treatment in several phase 3 clinical trials (Bernstein et al. Lancet Respir Med. doi:10.1016 / S2213-2600(19)30372-8 (February 2020)).

[0004] Tysabri® (natalizumab) is an anti-very late antigen (VLA)-4 humanized monoclonal IgG4 antibody that inhibits lymphocyte migration across the blood-brain barrier by blocking the interaction of VLA-4 with vascular cell adhesion molecule (VCAM)-1 and reducing inflammatory pathology. Natalizumab is a biotherapeutic drug approved for the treatment of multiple sclerosis. Progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the John Cunningham virus (JCV) that occurs exclusively in immunocompromised patients, has occurred in a small subset of patients receiving natalizumab. The use of extended-interval IV administration regimens to minimize the risk of PML has previously been disclosed (WO2019 / 085335). Subcutaneous formulations of VLA-4 binding antibodies for monthly or bimonthly administration have also been disclosed (U.S. Patent No. 9,533,044). However, these two treatment approaches follow different routes and durations of administration. Thus, there remains a need for reliable biotherapeutic regimens that reduce pathological inflammation while administering therapeutically effective concentrations of biotherapeutics. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2019 / 085335 [Patent Document 2] U.S. Patent No. 9,533,044 [Non-patent literature]

[0006] [Non-Patent Document 1] Rummel et al.,Ann. Oncol. 2017;28(4):836-842 [Non-patent document 2] Dychter et al., J. Infus Nurs. 2012;35(3):154-160 [Non-patent document 3] Bittner et al., Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities.BioDrugs, 32:425-440, 2018 [Non-patent document 4] Bernstein et al. Lancet Respir Med. doi:10.1016 / S2213-2600(19)30372-8 (February 2020) Summary of the Invention [Means for solving the problem]

[0007] The present disclosure provides an improved two-phase dosing regimen for reducing pathological inflammation caused by anti-VLA-4 antibodies, particularly natalizumab, including an induction phase using standard interval dosing (SID) followed by a chronic phase using extended interval dosing (EID). In some embodiments, the same dose administered during the SID phase can be administered during the EID phase. In preferred embodiments, subcutaneous administration is used during at least one treatment phase, and more preferably both treatment phases. In particular, as detailed herein, the inventors have surprisingly discovered that subcutaneous (SC) administration can be used in place of intravenous (IV) administration during one or both phases of the dosing regimen, significantly improving safety, cost, and patient compliance. Surprisingly, natalizumab trough concentrations and alpha-4 integrin saturation are similar between IV and SC administration, regardless of patient weight. Thus, in some embodiments, the same dose administered IV can be administered SC, thereby significantly simplifying clinical implementation and supply chain logistics. The improved regimens and methods provided herein reduce the risk of developing PML without significantly compromising efficacy.

[0008] Provided herein are methods for chronically reducing pathological inflammation in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an anti-VLA-4 antibody in a two-phase dosing regimen, the two-phase regimen comprising an induction phase comprising administering the anti-VLA-4 antibody once every two weeks, about once every two weeks, once every four weeks, about once every four weeks, once every 30 days, about once every 30 days, once a month, or about once a month for at least six months, more preferably at least eight, ten, or twelve months, followed by a chronic phase comprising administering the anti-VLA-4 antibody once every five to ten weeks, more preferably once every five, six, seven, or eight weeks. In some embodiments, the induction phase is 6 to 18 months, 8 to 16 months, 10 to 14 months, 11 months, 12 months, or 13 months. In certain embodiments, the induction phase is 12 months and the chronic phase comprises administration of the anti-VLA-4 antibody every 5 weeks, about every 5 weeks, every 6 weeks, about every 6 weeks, every 7 weeks, or about every 7 weeks, more preferably every 6 weeks or about every 6 weeks.

[0009] In some embodiments, the anti-VLA-4 antibody is natalizumab. In some embodiments, SC administration and amounts may be consistent with IV administration. In some embodiments, the therapeutically effective amount administered during the induction phase and chronic phase is the same, and the therapeutically effective amount is 250 to 450 mg (e.g., 250 mg, 300 mg, 350 mg, 400 mg, or 450 mg), more preferably about 300 mg, and even more preferably 300 mg. In some embodiments, the therapeutically effective amount administered SC during the chronic phase is 300 to 500 mg (e.g., 300 mg, 350 mg, 400 mg, 450 mg, or 500 mg). In some embodiments, the therapeutically effective amount is about 250 to about 450 mg (e.g., about 250 mg, about 300 mg, about 350 mg, about 400 mg, or about 450 mg), more preferably about 300 mg, and even more preferably 300 mg. In some embodiments, the therapeutically effective amount administered SC during the chronic phase is about 300 to about 500 mg (e.g., about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg), more preferably about 300 mg, and even more preferably 300 mg.

[0010] In preferred embodiments, at least one treatment phase, preferably both treatment phases, includes SC administration, preferably exclusively. In some embodiments, the induction phase includes SC administration, preferably exclusively. In some embodiments, the chronic phase includes SC administration, preferably exclusively. In some embodiments, both the induction phase and the chronic phase include SC administration, preferably exclusively. In an exemplary embodiment, the patient is not receiving natalizumab treatment, and the pathological inflammation is multiple sclerosis.

[0011] A further aspect of the present disclosure is a method of reducing the risk of developing progressive multifocal leukoencephalopathy (PML) in a subject with multiple sclerosis, comprising administering to the patient a therapeutically effective amount of an anti-VLA-4 antibody in a two-phase dosing regimen, the two-phase regimen comprising an induction phase comprising administering the anti-VLA-4 antibody once every two weeks, about once every two weeks, once every four weeks, about once every four weeks, once a month, or about once a month for at least six months, more preferably at least eight, ten, or twelve months, followed by a chronic phase comprising administering the anti-VLA-4 antibody once every five to ten weeks, more preferably once every five, six, seven, or eight weeks. In some embodiments, the induction phase is 6 to 18 months, 8 to 16 months, 10 to 14 months, 11 months, 12 months, or 13 months. In certain embodiments, the induction phase is 12 months and the chronic phase comprises administration of the anti-VLA-4 antibody every 5 weeks, about every 5 weeks, every 6 weeks, about every 6 weeks, every 7 weeks, or about every 7 weeks, more preferably every 6 weeks or about every 6 weeks.

[0012] In some embodiments, the anti-VLA-4 antibody is natalizumab. In some embodiments, SC administration and amounts may be consistent with IV administration. In some embodiments, the therapeutically effective amount administered during the induction phase and chronic phase is the same, and the therapeutically effective amount is 250 to 450 mg (e.g., 250 mg, 300 mg, 350 mg, 400 mg, or 450 mg), more preferably about 300 mg, and even more preferably 300 mg. In some embodiments, the therapeutically effective amount administered SC during the chronic phase is 300 to 500 mg (e.g., 300 mg, 350 mg, 400 mg, 450 mg, or 500 mg). In some embodiments, the therapeutically effective amount is about 250 to about 450 mg (e.g., about 250 mg, about 300 mg, about 350 mg, about 400 mg, or about 450 mg), more preferably about 300 mg, and even more preferably 300 mg. In some embodiments, the therapeutically effective amount administered SC during the chronic phase is about 300 to about 500 mg (e.g., about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg), more preferably about 300 mg, and even more preferably 300 mg.

[0013] In preferred embodiments, at least one treatment phase, preferably both treatment phases, comprises SC administration. In some embodiments, the induction phase comprises SC administration, preferably exclusively SC administration. In some embodiments, the chronic phase comprises SC administration, preferably exclusively SC administration. In some embodiments, both the induction phase and the chronic phase comprise SC administration, preferably exclusively SC administration. In an exemplary embodiment, the patient is not receiving natalizumab treatment and the pathological inflammation is multiple sclerosis.

[0014] In another aspect, the invention provides a method of administering natalizumab to a patient in need thereof according to a two-phase treatment protocol, comprising administering natalizumab therapy on a SID schedule at 4-week intervals over an induction phase of at least 12 months, followed by chronic administration of natalizumab therapy on an EID schedule at intervals of at least 6 weeks, wherein one or both, preferably both, treatment phases comprise SC administration, and even more preferably comprise only SC administration. In certain embodiments, the chronic administration phase can be 6 to 48 months, 8 to 36 months, 12 to 24 months, or in other embodiments, can last more than 4 years, more than 8 years, or the patient's lifetime.

[0015] In some embodiments, the methods further comprise: a) measuring a soluble molecule in a first biological sample obtained from the patient during the induction phase, wherein the soluble molecule is sVCAM; b) measuring sVCAM in a second biological sample obtained from the individual during the chronic phase; c) determining whether there is an increase in the level of sVCAM between the first and second biological samples within an acceptable range (e.g., greater than about 0 to less than about 600 ng / mL), which range correlates with an acceptable increase in immunosurveillance activity in the individual; and d) if there is an unacceptable increase in the level of sVCAM (e.g., >600 ng / mL), returning the patient to a 4-week SID schedule and / or a monthly dosing regimen, or increasing the dosing frequency of the EID schedule (e.g., every 5 weeks instead of every 6 weeks). In some embodiments, the first biological sample is obtained from the patient at least 6 months after the start of the induction phase, and the second biological sample is obtained within 6 months of the start of the chronic phase.

[0016] In some embodiments, the methods further comprise: a) measuring a soluble molecule in at least one first biological sample obtained from the patient during the induction phase, wherein the soluble molecule is neurofilament light chain (Nf-L); b) measuring Nf-L in at least one second biological sample obtained from the individual during the chronic phase; c) determining whether there is an increase in the level of Nf-L between the first and second biological samples, wherein the increase correlates with ongoing neuronal damage in the individual; and d) if there is an increase, returning the patient to a SID schedule every 4 weeks and / or a monthly dosing regimen, or increasing the dosing frequency of the EID schedule (e.g., dosing every 5 weeks instead of every 6 weeks). In some embodiments, the first biological sample is obtained from the patient at least 6 months after the start of the induction phase, and the second biological sample is obtained within 6 months of the start of the chronic phase.

[0017] Another aspect of the present disclosure provides a method of improving the efficacy of chronic natalizumab therapy, comprising administering a therapeutically effective amount of natalizumab to a subject on a SID schedule every 4 weeks for at least 12 months, followed by chronically administering a therapeutically effective amount of natalizumab to the subject on an EID schedule every 6 weeks, monitoring whether the mean trough saturation of α4-integrin receptors is greater than 40, 50, 60, or 70% in the patient, and returning the patient to the SID schedule if the saturation of the α4-integrin receptors falls below a required threshold, wherein one or both of the SID schedule and the EID schedule, preferably both, comprise SC administration. In some embodiments, the SID and / or EID schedule, preferably both, comprise a 300 milligram dose.

[0018] In some embodiments, monitoring mean trough saturation of the α4-integrin receptor comprises: a) measuring a soluble molecule in a biological sample obtained from the patient while on a SID schedule, where the soluble molecule is sVCAM; b) measuring sVCAM in a second biological sample obtained from the individual while on an EID schedule; c) determining whether there is an increase in the level of sVCAM between the first and second biological samples, where the increase correlates with increased α4 integrin activity in the individual; and d) if there is an increase above a threshold amount (e.g., >600 ng / mL), returning the patient to a SID schedule or increasing the dosing frequency of the EID schedule (e.g., dosing every 5 weeks instead of every 6 weeks). In some embodiments, the first biological sample is obtained from the patient at least 6 months after initiation of the SID schedule, and the second biological sample is obtained within 6 months of initiation of the EID schedule.

[0019] In some embodiments, the subject has an autoimmune disease. In some embodiments, the autoimmune disease is MS. In some embodiments, the autoimmune disease is inflammatory bowel disease. In some embodiments, the autoimmune disease is Crohn's disease. In some embodiments, the subject has been diagnosed with or has epilepsy.

[0020] This patent or patent application contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief explanation of the drawings]

[0021] [Figure 1]Distribution of simulated natalizumab steady-state PD / PK parameters. Boxes indicate the interquartile range, and whiskers indicate the range excluding outliers. Open circles represent outliers greater than or less than 1.5 times the value of the first or third quartile. The horizontal line within each box represents the median. Cavg is defined as AUCtau / tau, where tau is 672 hours. Ctrough is the minimum natalizumab serum concentration or α4-integrin saturation. [Figure 2] PK profiles of natalizumab after IV and SC treatment are shown. Arrows indicate the time of administration. [Figure 3] 1 shows the levels of alpha-4 integrin saturation over time after IV and SC treatment with natalizumab. The arrow indicates the time of administration. [Figure 4] 1 shows soluble VCAM levels over time after IV and SC treatment with natalizumab. Arrows indicate the time of administration. [Figure 5-1] Pharmacokinetic profiles after different dosing regimens, Q4W or Q6W (after 12 months of Q4W natalizumab treatment), are shown. Baseline mean trough concentrations were similar in both the Q6W and Q4W groups (Q6W: 34.0929 μg / mL; Q4W: 34.2811 μg / mL). Mean trough concentrations after the Q6W and Q4W dosing intervals ranged from 10 μg / mL to 21 μg / mL for Q6W and from 33 μg / mL to 38 μg / mL for Q4W. In general, mean trough concentrations after the Q6W dosing interval were approximately 60% to 70% lower than those observed with the Q4W dosing interval. Administration was by IV. [Figure 5-2] Pharmacokinetic profiles after different dosing regimens, Q4W or Q6W (after 12 months of Q4W natalizumab treatment), are shown. Baseline mean trough concentrations were similar in both the Q6W and Q4W groups (Q6W: 34.0929 μg / mL; Q4W: 34.2811 μg / mL). Mean trough concentrations after the Q6W and Q4W dosing intervals ranged from 10 μg / mL to 21 μg / mL for Q6W and from 33 μg / mL to 38 μg / mL for Q4W. In general, mean trough concentrations after the Q6W dosing interval were approximately 60% to 70% lower than those observed with the Q4W dosing interval. Administration was by IV. [Figure 6-1] Pharmacodynamic profiles after different dosing regimens, Q4W or Q6W, after 12 months of Q4W natalizumab treatment are shown. Observations <10% or >150% are not shown in the plots (n=4 for Q4W, n=22 for Q4W-Q6W). At baseline, mean trough α4 integrin saturation in MNC was similar in both the Q4W and Q6W treatment groups. With the Q6W dosing interval, α4 integrin saturation decreased by 8%-12% at week 12 and then remained stable at >63% throughout the study. With the Q4W dosing interval, α4 integrin saturation remained consistently >76% throughout the study. α4 integrin saturation was 9%-16% lower at each time point in the Q6W group compared with the Q4W group. [Figure 6-2] Pharmacodynamic profiles after different dosing regimens, Q4W or Q6W, after 12 months of Q4W natalizumab treatment are shown. Observations <10% or >150% are not shown in the plots (n=4 for Q4W, n=22 for Q4W-Q6W). At baseline, mean trough α4 integrin saturation in MNC was similar in both the Q4W and Q6W treatment groups. With the Q6W dosing interval, α4 integrin saturation decreased by 8%-12% at week 12 and then remained stable at >63% throughout the study. With the Q4W dosing interval, α4 integrin saturation remained consistently >76% throughout the study. α4 integrin saturation was 9%-16% lower at each time point in the Q6W group compared with the Q4W group. [Figure 7] Figure 1 shows IV and SC natalizumab steady-state C troughs following administration of natalizumab 300 mg Q6W. The upper and lower boundaries of the box represent the 75th and 25th percentiles, respectively. The solid line within the box represents the median. The whiskers represent the 97.5th and 2.5th percentiles of the simulated results. [Figure 8]Steady-state C trough IV and SC α-4-integrin saturation after administration of natalizumab 300 mg Q6W is shown. The upper and lower boundaries of the box represent the 75th and 25th percentiles, respectively. The solid line within the box represents the median. The whiskers represent the 97.5th and 2.5th percentiles of the simulated results. [Figure 9] Predicted steady-state trough (A) natalizumab concentrations and (B) α-integrin saturation following SC 300 mg Q4W dosing by body weight are shown. [Figure 10] Predicted steady-state trough (A) natalizumab concentrations and (B) α-integrin saturation following SC 300 mg Q4W dosing with prior natalizumab exposure are shown. [Figure 11] Model-predicted (A) steady-state trough pharmacokinetic (natalizumab concentration) and (B) pharmacodynamic (alpha-4 integrin saturation) endpoints by weight category are shown. Predicted steady-state Q6W natalizumab concentrations and alpha-4 integrin saturation decreased with increasing body weight, similarly for intravenous and subcutaneous administration. DETAILED DESCRIPTION OF THE INVENTION

[0022] Natalizumab, marketed under the trade name TYSABRI® (BIOGEN®, MA), is an integrin receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple sclerosis and Crohn's disease. The standard FDA-approved dosing regimen is 300 milligrams (mg) administered intravenously over approximately one hour every four weeks. Among patients receiving natalizumab therapy, a small subpopulation develops progressive multifocal leukoencephalopathy (PML) (Plavina, T. et al. Ann Neurol 2014;76:802-12). Significant efforts have been made to identify and minimize this risk, including the development of various patient monitoring and alternative administration protocols. However, because the risks and efficacy of natalizumab are likely mechanistically related, balancing the safety of natalizumab treatment without simultaneously reducing its efficacy has proven challenging.

[0023] definition The subject referred to herein is generally a male or female human subject (patient) undergoing or to be undergoing treatment with natalizumab for a particular condition. The condition may be an autoimmune condition or an inflammatory condition. Autoimmune conditions are often considered inflammatory conditions, and vice versa; thus, in some embodiments, the subject has an autoimmune condition and / or an inflammatory condition. An autoimmune condition is a condition in which the subject's immune system attacks the subject's own cells / tissues. Non-limiting examples of autoimmune conditions include multiple sclerosis (MS) (e.g., relapsing-remitting MS, secondary progressive MS, and / or primary progressive MS), Crohn's disease, rheumatoid arthritis, lupus erythematosus, celiac disease, Sjogren's syndrome, polymyalgia rheumatica, ankylosing spondylitis, type 1 diabetes, alopecia areata, vasculitis, and temporal arteritis.

[0024] As used herein, "about" refers to within 0.1% to 5% of a given value (e.g., within 5%, 3%, 2%, 1%, 0.5%, 0.1% of a given value). When amounts and other specified values ​​are described herein, allowed deviations are within pharmaceutically acceptable standards.

[0025] The indefinite articles "a" and "an," as used herein in the specification and claims, unless expressly indicated otherwise, should be understood to mean "at least one."

[0026] It is also to be understood that, unless expressly stated otherwise, in any method claimed herein that includes more than one step or action, the order of the method steps or actions is not necessarily limited to the order in which the steps or actions of the invention are recited.

[0027] In the claims and the foregoing specification, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like, are to be understood as open-ended, i.e., to mean inclusive without limitation. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as defined in U.S. Patent Office Manual of Patent Examining Procedure, Section 2111.03.

[0028] The terms "about" and "substantially" preceding a numerical value mean ±10% of the recited numerical value.

[0029] When a range of values ​​is given, each value between the upper and lower limits of the range is specifically contemplated and described herein. A "pharmaceutically effective amount" or "therapeutically effective amount," used interchangeably, is an amount sufficient to cure or at least partially arrest the symptoms of a disease and / or complications of a disease.

[0030] An "anti-VLA-4 antibody" is an anti-very late antigen (VLA)-4 monoclonal antibody, a humanized, human, or chimeric anti-VLA-4 monoclonal antibody.

[0031] A two-phase dosing regimen herein refers to the administration of natalizumab in at least two phases, e.g., an induction phase and a chronic phase. Preferably, the induction phase comprises the administration of natalizumab on a SID schedule, and the chronic phase comprises the administration of natalizumab on an EID schedule. In some embodiments, the induction phase comprises the administration of natalizumab once every 2 weeks, about once every 2 weeks, once every 3 weeks, about once every 3 weeks, once every 4 weeks, about once every 4 weeks, once every 30 days, about once every 30 days, once monthly, or about once monthly, for at least 6 months, more preferably at least 8, 10, or 12 months. In some embodiments, the induction phase is 6 to 18 months, 8 to 16 months, 10 to 14 months, 11 months, 12 months, or 13 months. In some embodiments, the chronic phase involves administration of natalizumab once every 5 to 10 weeks, more preferably once every 5 weeks, about every 5 weeks, about every 6 weeks, about every 6 weeks, about every 7 weeks, about every 7 weeks, about every 8 weeks, or about every 8 weeks. In certain embodiments, both the induction phase and the chronic phase involve SC administration, and preferably involve only SC administration.

[0032] As used herein, extended interval dosing (EID) refers to the administration of natalizumab at intervals longer than the standard interval dosing (SID) schedule of 300 mg every 4 weeks. An EID schedule should not exceed 12 doses of natalizumab in a 12-month period (30 days per month), and usually should not exceed 11 or 10 doses in a 12-month period (30 days per month). Therefore, a SID schedule should exceed 10 doses of natalizumab in a 12-month period, and usually exceed 11 or 12 doses in a 12-month period. In some embodiments, the EID schedule interval for administering natalizumab (e.g., 300 mg doses) is at least 5 weeks (35 days). For example, the EID schedule interval can be at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, or at least 10 weeks. In some embodiments, the EID schedule interval is 5 to 12 weeks. For example, the EID schedule interval can be 5 to 10 weeks, 5 to 9 weeks, 5 to 8 weeks, 5 to 7 weeks, or 5 to 6 weeks. In some embodiments, the EID schedule interval is about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, or about 10 weeks. In some embodiments, the EID schedule interval is 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, or 10 weeks. In some embodiments, the EID schedule interval is 5 weeks and 1 day, 5 weeks and 2 days, 5 weeks and 3 days, 5 weeks and 4 days, 5 weeks and 5 days, or 5 weeks and 6 days. In some embodiments, the EID schedule interval is 6 weeks and 1 day, 6 weeks and 2 days, 6 weeks and 3 days, 6 weeks and 4 days, 6 weeks and 5 days, or 6 weeks and 6 days. In some embodiments, the EID schedule is 7 weeks and 1 day, 7 weeks and 2 days, 7 weeks and 3 days, 7 weeks and 4 days, 7 weeks and 5 days, or 7 weeks and 6 days. In some embodiments, the EID schedule interval is 8 weeks and 1 day, 8 weeks and 2 days, 8 weeks and 3 days, 8 weeks and 4 days, 8 weeks and 5 days, or 8 weeks and 6 days. In some embodiments, the EID schedule interval is 9 weeks and 1 day, 9 weeks and 2 days, 9 weeks and 3 days, 9 weeks and 4 days, 9 weeks and 5 days, or 9 weeks and 6 days.

[0033] In some embodiments, the interval between the EID schedule and / or chronic phase of the dosing regimen is greater than 4 weeks and less than 10 weeks, or greater than about 4 weeks and less than about 10 weeks. In some embodiments, the interval between the EID schedule and / or chronic phase of the dosing regimen is at least 5 weeks and less than 10 weeks, or at least about 5 weeks and less than about 10 weeks. In some embodiments, the interval between the EID schedule and / or chronic phase of the dosing regimen is greater than 5 weeks or about 5 weeks and not greater than 6, 7, or 8 weeks or not greater than about 6, 7, or 8 weeks. In some embodiments, the interval between the EID schedule and / or chronic phase of the dosing regimen is at least about 6 weeks and not greater than about 9 weeks. In some embodiments, the interval between the EID schedule and / or chronic phase of the dosing regimen is greater than 5 weeks and not greater than 8 weeks, or greater than about 5 weeks and not greater than about 8 weeks. In some embodiments, the interval between the EID schedule and / or chronic phase of the dosing regimen is at least 6 weeks and not greater than 8 weeks, or at least about 6 weeks and not greater than about 8 weeks. In certain embodiments, the chronic administration period may be 6 months to 48 months, about 6 months to about 48 months, 8 months to 36 months, about 8 months to about 36 months, 12 months to 24 months, about 12 months to about 24 months, or in other embodiments, greater than 4 years, greater than about 4 years, greater than 8 years, greater than about 8 years, or for the life of the patient.

[0034] In some embodiments, the two-phase dosing regimen is selected to maintain a mean trough α4β1-integrin receptor saturation of greater than 40%, 45%, or 50% (or greater than 55%, 60%, 65%, or 70%), or at least about 40%, 45%, or 50% (or at least about 55%, 60%, 65%, or 70%), during both treatment periods in a patient population in need of natalizumab treatment. In some cases, the two-phase dosing regimen that maintains a mean trough α4β1-integrin receptor saturation of greater than 40%, 45%, 50%, 55%, 60%, 65%, or 70% of reference, or at least about 40%, 45%, 50%, 55%, 60%, 65%, or 70%, in a patient population in need of natalizumab treatment is a SID schedule for at least 12 months, followed by chronic administration on an EID schedule with an interval of greater than 5 weeks but not more than 10 weeks. In some cases, the EID schedule interval that maintains the reference mean trough α4β1-integrin receptor saturation during the chronic phase in a patient population requiring natalizumab treatment is an EID schedule having an interval of at least 6 weeks, more than 4 weeks but less than 10 weeks, more than 5 weeks but not more than 10 weeks, at least 6 weeks but not more than 10 weeks, or at least 6 weeks but not more than 7, 8, or 9 weeks.

[0035] In some cases, the two-phase dosing regimen comprises a SID schedule comprising administering natalizumab once every 2 weeks, about once every 2 weeks, once every 4 weeks, about once every 4 weeks, once every 30 days, about once every 30 days, once a month, or about once a month for at least 6 months, more preferably at least 8, 10, or 12 months, followed by an EID schedule comprising administering natalizumab once every 5 to 10 weeks, more preferably once every 5, 6, 7, or 8 weeks. In some embodiments, the SID schedule is 6 to 18 months, 8 to 16 months, 10 to 14 months, 11 months, 12 months, or 13 months. In certain embodiments, the SID schedule is 12 months, and the EID schedule comprises administering natalizumab every 5 weeks, about every 5 weeks, 6 weeks, about every 6 weeks, every 7 weeks, or about every 7 weeks, more preferably every 6 weeks or about every 6 weeks.

[0036] In some embodiments, the EID schedule comprises 15 or fewer administrations over an 18-month period. In other embodiments, the EID schedule comprises 10 or fewer administrations over a 12-month period. In some embodiments, the EID schedule comprises 10 or fewer administrations per year for the duration of the infusion history. In some embodiments, the EID schedule comprises at least 5 administrations during the chronic phase. In some embodiments, the EID schedule comprises at least 6 administrations during the chronic phase. In some embodiments, the EID schedule comprises 5 or more administrations during the chronic phase. In some embodiments, the EID schedule comprises 6 or more administrations during the chronic phase.

[0037] In some embodiments, the EID schedule is adhered to (administered) for at least 6 months. In some embodiments, the EID schedule is adhered to for at least 12 months (1 year). In some embodiments, the EID schedule is adhered to for at least 18 months. In some embodiments, the EID schedule is adhered to for at least 24 months (2 years). In some embodiments, the EID schedule is adhered to for at least 30 months. In some embodiments, the EID schedule is adhered to for at least 36 months (3 years). In some embodiments, the EID schedule is adhered to for at least 48 months (4 years). In some embodiments, the EID schedule is adhered to for at least 96 months (8 years). In some embodiments, the EID schedule is adhered to for the patient's lifetime.

[0038] In some embodiments, the SID schedule involves SC administration of 300 mg of natalizumab every 4 weeks (-2 / +5 days), e.g., until week 52. In some embodiments, the EID schedule involves SC administration of 300 mg of natalizumab every 6 weeks (-2 / +5 days), e.g., after week 52. In some embodiments, the EID schedule involves SC administration of 350 mg, 400 mg, 450 mg, or 500 mg of natalizumab every 6 weeks (-2 / +5 days), e.g., after week 52. In some embodiments, the EID schedule involves SC administration of 150 mg, 175 mg, 200 mg, 225 mg, or 250 mg of natalizumab every 3 weeks (-2 / +5 days), e.g., after week 52.

[0039] In some embodiments, monitoring mean trough saturation of the α4-integrin receptor comprises: a) measuring a soluble molecule in a first biological sample obtained from the patient while on a SID schedule, where the soluble molecule is sVCAM; b) measuring sVCAM in a second biological sample obtained from the individual while on an EID schedule; c) determining whether there is an increase in the level of sVCAM between the first and second biological samples, where the increase correlates with increased α4-integrin activity in the individual; and d) if there is an increase above a threshold amount (e.g., >600 ng / mL), returning the patient to the SID schedule or increasing the dosing frequency of the EID schedule (e.g., dosing every 5 weeks instead of every 6 weeks). In some embodiments, the first biological sample is obtained from the patient at least 6 months after initiation of the SID schedule, and the second biological sample is obtained within 6 months of initiation of the EID schedule.

[0040] Relevant biomarkers for determining and / or monitoring the efficacy of the two-phase treatment protocol provided herein include, for example, sVCAM and / or Nf-L. Without being bound by theory, increased saturation and / or occupancy of target α4 integrin on the surface of circulating lymphocytes by natalizumab leads to decreased surface expression of α4-integrin on lymphocytes and decreased serum concentrations of sVCAM. Accordingly, sVCAM provides an effective surrogate biomarker for α4-integrin receptor saturation and immunosurveillance activity in general (see, e.g., Plavina et al. Neurology (2017) 89(15):1584-1593). In contrast, neurofilament proteins such as Nf-L provide indicators of axonal damage and neuronal death and serve as effective surrogate biomarkers for ongoing disease activity, particularly in MS patients (see, e.g., Kuhle et al. Mult Scler. (2013) 19:1597-603; Varhaug et al., Front Neurol. (2019) 10: 338).

[0041] In alternative embodiments, the methods of the present invention further comprise determining and / or monitoring the effectiveness of the two-phase administration protocol disclosed herein, comprising: a) measuring soluble molecules in a first biological sample obtained from the patient during the induction phase, where the soluble molecules are sVCAM and / or Nf-L; b) measuring sVCAM and / or Nf-L in a second biological sample obtained from the individual during the chronic phase; c) determining whether there is an increase in the levels of sVCAM and / or Nf-L between the first and second samples above a predetermined threshold; and d) if there is an increase above one or both predetermined thresholds, returning the patient to a 4-weekly SID schedule and / or a monthly dosing regimen, or increasing the dosing frequency of the EID schedule (e.g., dosing every 5 weeks instead of every 6 weeks). In some embodiments, the first biological sample is obtained from the patient at least 6 months after the start of the induction phase, and the second biological sample is obtained within 6 months of the start of the chronic phase.

[0042] In some embodiments, the soluble marker is sVCAM and the predetermined threshold is >600 ng / mL. In some embodiments, the soluble marker is Nf-L and the predetermined threshold is any increase greater than the test-retest variability in the assay, whether at the patient level or population level. In some embodiments, the soluble marker is Nf-L and step c) comprises determining whether the second sample shows an increase above a sub-therapeutic or steady-state value established by the first sample for the individual patient, or above an established sub-therapeutic value derived from literature (see, e.g., Delcoigne et al., Neurology (2020) 94:e1201-e1212; Kuhle et al. J. Multiple Sclerosis (2020) 26(13):1691-99).

[0043] Treatment with natalizumab has also been shown to be associated with an increase in circulating immune cells from pre-natalizumab levels, particularly CD34+ hematopoietic progenitor cells, which increase above normal baseline levels (Polman et al., N. Engl J. Med (2006) 354:899-910; Bonig et al., Blood (2008) 111:3439-3441). Thus, in a further embodiment, the method of the invention further comprises determining the efficacy of the two-phase administration protocol by a) measuring blood lymphocytes and / or lymphocyte subsets in a first biological sample obtained from the patient during the induction phase, preferably the lymphocyte subsets comprising or selected from the group consisting of CD4+ T cells, CD8+ T cells, CD19+ B cells, CD56+ NK cells, and / or CD34+ / CD45+ hematopoietic progenitor cells; and b) measuring blood lymphocytes and / or lymphocyte subsets in a second biological sample obtained from the individual during the chronic phase. and / or measuring lymphocytes and / or one or more lymphocyte subsets; c) determining whether there is a change in the levels of lymphocytes and / or lymphocyte subsets between the first and second samples; and d) if there is a decrease in the total lymphocyte count and / or the number(s) of specific lymphocyte subsets between the induction phase and the chronic phase, returning the patient to a SID schedule every 4 weeks and / or a monthly dosing regimen or increasing the dosing frequency of the EID schedule (e.g., every 5 weeks instead of every 6 weeks). In some embodiments, the first biological sample is obtained from the patient at least 6 months after the start of the induction phase and the second biological sample is obtained within 6 months of the start of the chronic phase.

[0044] In some embodiments, 1×10 9 A decrease in total lymphocyte count above about 300 cells / mm indicates a potential decrease in efficacy of treatment and indicates a need to modify the patient's dosing schedule. In another embodiment, a decrease in total lymphocyte count above about 300 cells / mm indicates a potential decrease in efficacy of treatment and a need to modify the patient's dosing schedule. 3 A decrease in CD4+ T cell count of at least about 200 cells / mm indicates a potential decrease in efficacy of treatment and indicates a need to modify the patient's dosing schedule. In another embodiment, a decrease in CD4+ T cell count of at least about 200 cells / mm indicates a potential decrease in efficacy of treatment and indicates a need to modify the patient's dosing schedule. 3A decrease in CD8+ T cell count of at least about 300 cells / mm indicates a potential decrease in efficacy of treatment and indicates a need to modify the patient's dosing schedule. In another embodiment, a decrease in CD8+ T cell count of at least about 300 cells / mm indicates a potential decrease in efficacy of treatment and indicates a need to modify the patient's dosing schedule. 3 A decrease in CD19+ B cell count of at least about 100 cells / mm indicates a potential decrease in efficacy of treatment and indicates a need to modify the patient's dosing schedule. 3 A decrease in CD56+ NK cell count of at least about 5 cells / mm indicates a potential decrease in efficacy of treatment and a need to modify the patient's dosing schedule. 3 A decrease in CD34+ / CD45+ progenitor cell count indicates a potential decrease in therapeutic efficacy and indicates the need to modify the patient's dosing schedule.

[0045] As described herein, a two-phase administration regimen including SC administration is provided to enhance the safety of natalizumab treatment. In some embodiments, a two-phase administration regimen is provided to enhance the safety of chronic natalizumab therapy. Safety can be enhanced by reducing the risk of adverse events compared to SID. In an exemplary embodiment, a two-phase regimen reduces the risk of PML. In some cases, a two-phase regimen reduces the risk of PML, reduces the risk of inducing the production of anti-natalizumab antibodies, reduces the risk of patient sensitization to natalizumab, or a combination thereof. In some examples, a two-phase regimen reduces the risk of loss of efficacy of natalizumab treatment due to the production of anti-idiotypic antibodies to natalizumab in patients.

[0046] In some embodiments, the risk of developing PML in a subject receiving natalizumab in a two-phase dosing regimen described herein that includes SC administration is reduced by at least 20% compared to the risk of developing PML in a subject receiving natalizumab therapy on a SID schedule, and the effectiveness of natalizumab therapy is reduced by less than 10% relative to the effectiveness of SID. For example, the risk of developing PML in a subject receiving natalizumab in a two-phase dosing regimen that includes SC administration described herein is reduced by at least 30%, 40%, or 50% compared to the risk of developing PML in a subject receiving natalizumab therapy on a SID schedule every four weeks, and the effectiveness of natalizumab therapy is reduced by less than 10% relative to the effectiveness of SID.

[0047] The subject referred to herein is generally a male or female human subject (patient) undergoing or to be undergoing treatment with natalizumab for a particular condition. The condition may be an autoimmune condition or an inflammatory condition. Autoimmune conditions are often considered inflammatory conditions, and vice versa; thus, in some embodiments, the subject has an autoimmune condition and / or an inflammatory condition. An autoimmune condition is a condition in which the subject's immune system attacks the subject's own cells / tissues. Non-limiting examples of autoimmune conditions include multiple sclerosis (MS) (e.g., relapsing-remitting MS, secondary progressive MS, and / or primary progressive MS), Crohn's disease, rheumatoid arthritis, lupus erythematosus, celiac disease, Sjögren's syndrome, polymyalgia rheumatica, ankylosing spondylitis, type 1 diabetes, alopecia areata, vasculitis, and temporal arteritis. Many of the aforementioned conditions are also inflammatory conditions. Therefore, in some embodiments, the method of the present disclosure comprises identifying a subject for natalizumab therapy with a two-phase administration regimen comprising SC administration, or administering natalizumab therapy with a two-phase administration regimen comprising SC administration to the subject, wherein the subject has a high risk of PML and has an autoimmune condition.In some embodiments, the autoimmune condition is multiple sclerosis.In some embodiments, the autoimmune condition is Crohn's disease.

[0048] In some embodiments, the subject has been diagnosed with epilepsy. Epilepsy is a central nervous system disorder (neuropathy) in which the activity of neurons in the brain is inhibited, resulting in seizures or periods of abnormal behavior, agitation, and sometimes loss of consciousness. Thus, in some embodiments, the methods of the disclosure include identifying a subject for natalizumab therapy with a two-phase dosing regimen including SC administration, or administering natalizumab therapy to a subject with a two-phase dosing regimen including SC administration, wherein the subject has epilepsy, has recently had a seizure, or has epilepsy and has recently had a seizure. In some embodiments, the subject is at high risk of PML and has epilepsy, has recently had a seizure, or has epilepsy and has recently had a seizure.

[0049] In some embodiments, the subject has a prior history of immunosuppression. In some embodiments, the subject was treated with an immunosuppressant prior to receiving natalizumab therapy on a SID schedule every 4 weeks. In certain embodiments, the immunosuppressant is selected from the group consisting of mitoxantrone, methotrexate, mycophenolate mofetil, azathioprine, and cyclophosphamide.

[0050] A subject at high risk for PML is one who is seropositive for anti-JCV antibodies. In some embodiments, a high-risk subject for PML has previously received immunosuppression and is seropositive for anti-JCV antibodies. In some embodiments, a subject at risk for PML has an anti-JCV antibody index level (e.g., a mean index level) greater than 1.5. In some embodiments, a low-risk subject for PML is one who has an anti-JCV antibody index level (e.g., a mean index level) of 0.9 or less. The anti-JCV virus index value is calculated from a serum / plasma two-stage ELISA antibody assay (STRATIFY JCV™ Antibody (Indexed) and Reflex to Inhibition Assay; see, e.g., Lee, P. et al. J of Clin Virol, 2013;57(2):141-146, incorporated herein by reference). Antibody index levels, assays for assessing index levels, and the use of such index levels and assays for determining PML risk are described, for example, in WO 2012 / 166971 and WO 2014 / 193804.

[0051] A subject may be considered at high risk for PML if they test seropositive for anti-JCV antibodies before starting natalizumab therapy, or if they switch from a seronegative anti-JCV antibody state to a seropositive anti-JCV antibody state during natalizumab therapy. In some embodiments, a subject is considered at high risk for PML if they have an anti-JCV antibody index level of greater than 1.5 before starting natalizumab therapy, or if they switch from an anti-JCV antibody index level of 0.9 or less to an anti-JCV antibody index level greater than 1.5 during natalizumab therapy. For example, before starting natalizumab therapy, a subject may be tested for the presence or absence of anti-JCV antibodies. If the test results indicate that the subject is at low risk for PML (seronegative for anti-JCV antibodies, or has an anti-JCV antibody index level of 0.9 or less), the subject may be identified for natalizumab therapy on a SID schedule every 4 weeks. During the course of natalizumab therapy on a SID schedule, subjects may be retested for the presence of anti-JCV antibodies (e.g., tested monthly or every 2, 3, 4, 5, 6 months, or annually). If, upon retesting, the subject switches from seronegative to seropositive for anti-JCV antibodies, or from an anti-JCV antibody index level of 0.9 or less to an anti-JCV antibody index level of greater than 1.5, the subject may be identified as a candidate for natalizumab therapy on an EID schedule at least every 5 weeks.

[0052] Exemplary embodiments include a method of treating multiple sclerosis (MS) in a subject, comprising: a. administering a therapeutically effective amount of natalizumab to the subject on a SID schedule every 4 weeks for at least 12 months, followed by chronically administering a therapeutically effective amount of natalizumab to the subject on an EID schedule at least every 6 weeks; b. determining whether natalizumab therapy on the EID schedule maintains a trough saturation of α4-integrin of at least, or at least about, 40%, 45%, 50%, 55%, 60%, 65%, or 70%; and c. if the trough saturation of α4-integrin falls below a specified level, returning the patient to the SID schedule or increasing the dosing frequency of the EID schedule (e.g., administering every 5 weeks instead of every 6 weeks).

[0053] Exemplary embodiments include a method of treating Crohn's disease in a subject, comprising: a. administering a therapeutically effective amount of natalizumab to the subject on a SID schedule every 4 weeks for at least 12 months, followed by chronically administering a therapeutically effective amount of natalizumab to the subject on an EID schedule at least every 6 weeks; b. determining whether natalizumab therapy on the EID schedule maintains a trough saturation of α4-integrin of at least, or at least about, 40%, 45%, 50%, 55%, 60%, 65%, or 70%; and c. if the trough saturation of α4-integrin falls below a specified level, returning the patient to the SID schedule or increasing the dosing frequency of the EID schedule (e.g., administering every 5 weeks instead of every 6 weeks).

[0054] In some cases of one or more exemplary embodiments, step (b) comprises: a) measuring a soluble molecule in a biological sample obtained from the patient during a SID schedule, where the soluble molecule is sVCAM; b) measuring sVCAM in a second biological sample obtained from the individual during an EID schedule; and c) determining whether there is an increase in the level of sVCAM between the first and second biological samples, where the increase correlates with a decrease in trough saturation of α4-integrin in the individual. In some embodiments, the first biological sample is obtained from the patient at least 6 months after initiation of the SID schedule, and the second biological sample is obtained within 6 months of initiation of the EID schedule.

[0055] Although the above-described two-phase administration regimen is described with respect to natalizumab therapy, it is understood that such a two-phase regimen is likely to be suitable for use with other α4-integrin binding antibodies that increase the risk of PML, particularly those that bind to the same epitope or compete for epitope binding with natalizumab, or that inhibit lymphocyte trafficking to the brain.

[0056] Example Example 1: Pharmacokinetics and Pharmacodynamics of Natalizumab After Subcutaneous and Intravenous Administration Every 4 Weeks BACKGROUND: Natalizumab 300 mg intravenous (IV) infusion every 4 weeks (Q4W) is an effective treatment for patients with relapsing forms of multiple sclerosis, working by binding to lymphocyte alpha-4 integrin and preventing lymphocyte migration from the vasculature to the central nervous system. Subcutaneous (SC) administration may be preferred by patients due to its convenience and time savings compared with IV administration. SC natalizumab is being developed and tested in two clinical trials: DELIVER (NCT00559702) and REFINE (NCT01405820).

[0057] Objective: To characterize the pharmacokinetic (PK) / pharmacodynamic (PD) (alpha-4 integrin saturation) profile of natalizumab after single and multiple doses of SC administration and to aid in SC dose selection using simulations based on a population PK / PD model to achieve similar efficacy to 300 mg IV.

[0058] Methods: In DELIVER, single-dose PK / PD data were collected over 8 weeks with sampling at 4 hours and on days 1, 2, 3, 4, 7, 14, 21, 28, 35, 42, and 56, and multiple-dose trough PK / PD data were collected for six additional doses over 24 weeks. A population PK / PD model was previously developed using clinical data from 11 clinical trials. Steady-state natalizumab trough serum concentrations and alpha-4 integrin saturation over time for natalizumab 300, 350, 400, and 450 mg administered SC Q4W were simulated for 1,000 subjects per SC dose and compared to the PK / PD profile for natalizumab 300 mg administered IV Q4W.

[0059] Results: After a single SC dose, natalizumab concentrations peaked at approximately 168 hours (7 days) and 4 hours for SC and IV administration, respectively, as seen in Table 1. The elimination phase was similar for SC and IV administration. Saturation of alpha-4 integrin occurred rapidly, with saturation exceeding 80% within 4 hours. PD was similar for IV and SC administration at all time points assessed. With multiple doses, natalizumab trough concentrations and corresponding alpha-4 integrin saturation levels were similar for SC and IV administration. The lowest SC trough concentration observed with the 300 mg dose was 22 mg / mL, which is higher than the concentration resulting in a complete PD response (defined as the concentration resulting in 70% alpha-4 integrin binding). [Table 1]

[0060] Conclusions: Observed PD with single and multiple doses and simulations performed using population PK / PD modeling indicate that the 300 mg SC dose results in similar alpha-4 integrin saturation as the 300 mg IV dose. These data support the 300 mg SC dose and are predicted to provide efficacy similar to the currently approved 300 mg IV dose.

[0061] Example 2: Comparison of Modeling and Simulation of Natalizumab Pharmacokinetics and Pharmacodynamics After Intravenous and Subcutaneous Administration Every 6 Weeks Background: Intravenous (IV) administration of natalizumab 300 mg approximately every 6 weeks (Q6W) significantly reduces the risk of progressive multifocal leukoencephalopathy compared with IV administration of natalizumab 300 mg every 4 weeks (Q4W). Subcutaneous (SC) natalizumab has been developed and tested in two clinical trials, DELIVER (NCT00559702) and REFINE (NCT01405820), and SC administration is expected to be more convenient and time-saving compared with IV administration. Clinical trials suggest that 300 mg IV Q4W and SC administration have comparable pharmacodynamics (PD) and efficacy. No clinical trials have provided pharmacokinetic (PK) / PD or efficacy data for natalizumab administered SC Q6W.

[0062] Objective: To simulate the PK / PD profile of natalizumab administered SC Q6W using an existing natalizumab population PK / PD model and compare these simulations with predicted IV Q6W data and interim observed PK / PD data for IV Q6W administration from the NOVA clinical trial (NCT03689972).

[0063] Methods: Natalizumab trough concentrations (PK) and alpha-4 integrin saturation (PD) following 300 mg Q6W IV and SC administration were simulated using an existing population PK / PD model. A hypothetical population of 1,000 subjects with final parameter estimates from the model and covariate distributions observed in previous clinical trials was used in the simulation. PK / PD outcomes (10,000 simulated subjects) for patients switched to Q6W dosing after 1 year of Q4W dosing were compared with interim PK / PD outcomes observed in patients on the same dosing regimen in NOVA.

[0064] Results: The predicted median steady-state natalizumab trough concentrations and α-4 integrin saturation (95% prediction intervals) for IV and SC administration of Q6W were comparable (7.22 (0.61-24.76) mg / mL and 6.11 (0.58-18.39) mg / mL, respectively; 71.4% (15.8%-99.8%) and 68.6% (14.8%-97.8%), respectively). Median α-4 integrin saturation was ≥70% for both IV and SC administration of Q6W. Predicted steady-state Q6W natalizumab concentrations (PK) and α-4 integrin saturation (PD) each decreased similarly with increasing body weight (Figure 11). The model-predicted PK and PD ranges after switching to IV administration of Q6W encompass the observed data from NOVA.

[0065] Conclusions: These results predict that natalizumab trough concentrations and alpha-4 integrin saturation will be similar for IV and SC administration Q6W, suggesting that similar efficacy and safety profiles can be expected for IV and SC administration. The agreement between observed and predicted data for IV Q6W administration supports the reliability of the model's predictive ability. PK / PD data for SC administration of natalizumab Q6W from the planned NOVA open-label extension study may provide further validation of the model.

[0066] Example 3: Switching to 6-weekly natalizumab versus continuing 4-weekly dosing in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial (NOVA) BACKGROUND: Patients with relapsing-remitting multiple sclerosis (RRMS) who switched from every 4 weeks (Q4W) natalizumab treatment to an extended dosing interval of approximately every 6 weeks (Q6W) had a significantly reduced risk of progressive multifocal leukoencephalopathy (PML) compared with patients on the Q4W regimen. We conducted a randomized clinical trial to evaluate the efficacy of Q6W dosing of natalizumab in patients with RRMS.

[0067] Objective: To test the efficacy of EID and Q4W dosing of natalizumab in comparable patients switched to EID (approximately Q6W dosing frequency) after 1 to 2 years of stable treatment with Q4W.

[0068] Methods: NOVA was a prospective, open-label, assessor-blinded, multinational, controlled trial in which patients from 89 investigational sites treated with natalizumab 300 mg Q4W intravenous infusion for ≥12 months were randomized 1:1 to switch to intravenous natalizumab Q6W or continue Q4W treatment. The primary endpoint was the number of new / newly enlarging T2 (N / NET2) hyperintense lesions on MRI at week 72, assessed in a modified intention-to-treat population (all randomized patients who received at least one dose of study treatment and had at least one post-baseline efficacy assessment). Safety was assessed in all randomized patients who received at least one dose of study treatment. NOVA is registered with clinicaltrials.gov (NCT03689972).

[0069] RESULTS: Between December 26, 2018, and August 30, 2019, 499 patients were randomly assigned to 89 study sites. Of these, 251 were randomly assigned to receive natalizumab Q6W and 248 were assigned to receive continued treatment with natalizumab Q4W. Approximately equal proportions of Q6W (207 of 251 [82%]) and Q4W (195 of 248 [79%]) patients completed the study. Baseline demographic and disease characteristics of the Q6W (n=247) and Q4W (n=242) mITT populations were well balanced, including similar median MS disease duration (10.0 years and 9.0 years), median number of relapses in the previous year (both 1.0 years), and median length of natalizumab exposure before randomization (both 4.0 years) (Table 2). Compliance to last dose was 100% for Q6W patients and 99.9% for Q4W patients. The mean natalizumab dosing interval was 6.0 (standard deviation [SD] 0.06) weeks for Q6W patients and 4.0 (SD 0.08) weeks for Q4W patients. [Table 2-1] [Table 2-2]

[0070] Concurrent events (events leading to treatment discontinuation) were reported in 46 of 247 patients (18.6%) in the Q6W group and 51 of 242 patients (21.1%) in the Q4W group; the mean time to the first concurrent event was similar in both groups (33.1 [SD, 18.75] weeks in the Q6W group and 30.3 [SD, 21.83] weeks in the Q4W group). Most concurrent events were unrelated to treatment (35 of 46 [76.1%] in the Q6W group and 44 of 51 [86.3%] in the Q4W group), or information on the reason for the event was unavailable (4 of 46 [8.7%] in the Q6W group and 4 of 51 [7.8%] in the Q4W group). Concurrent events due to INEC-confirmed relapse were reported at similar rates in both groups (7 of 247 [2.8%] in Q6W; 5 of 242 [2.1%] in Q4W). However, the number of relapsed patients who chose rescue therapy was unbalanced between the two groups: 6 of 7 Q6W patients chose any rescue therapy after relapse, compared with no Q4W patients.

[0071] The primary endpoint (number of new / newly enlarging T2 lesions at week 72) was 0.20 (95% CI: 0.07, 0.63) in the Q6W group and 0.05 (95% CI: 0.01, 0.31) in the Q4W group (ratio, 4.24 [95% CI: 0.86, 20.85]; p = 0.076) with the treatment strategy Estimand and 0.31 (95% CI: 0.12, 0.82) in the Q6W group and 0.06 (95% CI: 0.01, 0.31) in the Q4W group (ratio, 4.93 [95% CI: 1.05, 23.20]; p = 0.044) with the hypothetical strategy Estimand (Table 3). [Table 3-1] [Table 3-2]

[0072] The distribution of patients with zero (78.1% and 81.8%), one (2.9% and 2.0%), or two (0.4% and 0.8%) new / newly enlarging T2 lesions at week 72 was similar in the Q4W and Q6W treatment groups, respectively. However, two patients in the Q6W group had five or more lesions, whereas no Q4W patients had two or more lesions. Of these two Q6W patients, patient 1 had no new disease activity during treatment but discontinued natalizumab at week 55 due to the development of anti-JCV seropositivity and relapsed at week 67. A subsequent MRI showed 30 new / newly enlarging T2 lesions. Because patient 1's T2 lesion growth occurred outside of treatment, patient 1 contributed only to the treatment strategy estimate; the 30 lesion values ​​were not used to impute data for the other Q6W patients with missing data. Patient 2 was diagnosed with asymptomatic PML after completing 72 weeks of treatment. Routinely scheduled MRI scans revealed the presence of five new / newly enlarging T2 lesions at week 24, 10 additional lesions at week 48, and 10 more at week 72 (for a total of 25 lesions). Because patient 2's T2 lesion growth occurred during treatment, this patient contributed to the assessment of the primary endpoints for both the treatment strategy estimand and hypothetical strategy estimand. Furthermore, the T2 lesion value at week 72 (25) was used as the worst value during treatment for the six Q6W patients who selected any rescue therapy.

[0073] No significant differences in secondary clinical outcomes were observed in mITT patients randomized to natalizumab Q6W or Q4W administration. The cumulative probability of recurrence at week 72 was similar for Q6W and Q4W (0.97 and 0.98), as was the estimated time to first recurrence (hazard ratio [HR], 1.31 [95% CI: 0.42, 4.13]; p=0.64). There was no significant difference in ARR at week 72 between Q6W and Q4W patients (0.00013 [95% CI: 0.00006, 0.00027] vs. 0.00010 [95% CI: 0.00004, 0.00024]; ratio, 1.32481 [95% CI (0.42016, 4.17725]; p=0.63). The cumulative probability of 24-week CDW at week 72 was similar in both groups (Q6W 0.90; Q4W 0.92), as was the time to 24-week CDW (HR, 1.29 [95% CI: 0.71, 2.34]; p=0.40).

[0074] Secondary MRI outcomes at all time points were similar in 247 Q6W mITT patients and 242 Q4W mITT patients. At week 72, one Q6W patient and one Q4W patient (0.4% each) had a Gd+ lesion. The Q6W patient with five or more Gd+ lesions at week 72 was the same patient who had 30 new / newly enlarging T2 lesions after treatment discontinuation (Patient 1, above). At the same time point, three Q6W patients (1.2%) and two Q4W patients (0.8%) had new T1 hypointense lesions. One of the Q6W patients with T1 hypointense lesions was Patient 1, and the other was an asymptomatic PML case with 25 new / newly enlarging T2 lesions (Patient 2, above). At week 48, seven Q6W patients (2.8%) and six Q4W patients (2.5%) had new / newly enlarging T2 lesions. In the Q6W group, patient 1 (30 lesions at week 72) and patient 2 (25 lesions at week 72) had 0 and 15 lesions, respectively, at week 48. All lesions were treated as MS in the prespecified analysis, but the etiology of patient 2's T2 lesions at weeks 24 and 48 is unknown.

[0075] The safety population included 250 Q6W and 247 Q4W patients. The incidence of AEs and SAEs was similar between the two treatment groups. During the course of the study, 17 of 250 Q6W patients (6.8%) and 17 of 247 Q4W patients (6.9%) experienced an SAE. AEs leading to discontinuation of study treatment were reported in 4 of 250 Q6W patients (1.6%) and 1 of 247 Q4W patients (0.4%). No deaths were reported in either group.

[0076] One case of PML (Patient 2, above) occurred in the natalizumab Q6W treatment group but none in the Q4W group. Patient 2 had known risk factors for PML, including a total natalizumab exposure period of 2 years (1 year before study enrollment and 1 year of Q4W dosing during the study) and an anti-JCV antibody index above the assay detection limit (reported as >2.35) at enrollment and all subsequent evaluations. After 7 years of injectable or oral DMT treatment, this patient had not received any DMT treatment for 1 year before initiating natalizumab. This case was classified as asymptomatic PML and is ongoing.

[0077] The exploratory NEDA endpoint was achieved by similar proportions of patients in both groups (173 of 247 [70.0%] in Q6W; 163 of 242 [67.4%] in Q4W; OR 1.195%, CI 0.8–1.7; p = 0.52).

[0078] Because optional rescue was not balanced between groups based on recurrence criteria, ad hoc analyses were performed to assess whether differences in the frequency or severity of recurrence could explain this imbalance. Among patients meeting rescue criteria in the Q6W and Q4W groups, the proportions of patients who required steroid treatment (4 of 7 [57.1%] vs. 4 of 5 [80.0%]) or hospitalization (1 of 7 [14.3%] vs. 1 of 5 [20.0%]) were similar between the two groups, indicating that the frequency and severity of recurrence events were similar overall despite the observed imbalance in the proportion of patients receiving rescue treatment.

[0079] Conclusions: The results of this study demonstrate that disease activity remains low in patients who switch to Q6W treatment after at least one year of stable natalizumab Q4W therapy. This finding further suggests that the majority of patients stable on natalizumab Q4W can be switched to Q6W treatment with little or no clinically significant loss of efficacy. The safety profile of natalizumab Q6W was similar to that of Q4W therapy, and no new safety signals were identified.

[0080] Pharmacokinetic and pharmacodynamic conclusions: The mean trough concentrations in the Q6W group were approximately 60%-70% lower compared to the Q4W group. Even with lower PK exposure in the Q6W group compared to the Q4W group, α4 integrin saturation (in MNCs, monocytes, lymphocytes, B cells, T cells, and dendritic cells) was comparable between the Q6W and Q4W groups, with the difference in α4 integrin saturation ranging from 9% to 16% (see e.g., Figures 5 and 6).

[0081] Example 4: Subject Preference for Subcutaneous (SC) and Intravenous (IV) Routes of Natalizumab Administration Background: Patients with relapsing-remitting multiple sclerosis (RRMS) who participated in the randomized controlled trial (NOVA) disclosed in Example III will participate in an open-label crossover extension (OLE) study including subcutaneous and intravenous.

[0082] Objective: To assess subject preference for SC versus IV routes of natalizumab administration and to examine the long-term efficacy, safety, and tolerability of EID.

[0083] Methods: Subjects enrolled in the study disclosed in Example 3 will receive natalizumab 300 mg via IV infusion once every 6 weeks (42 ± 7 days) for 36 weeks and will be randomized to an additional 48 weeks of crossover treatment consisting of 24 weeks of SC administration EID Q6W and 24 weeks of IV administration EID Q6W. All MRI scans will be read by blinded assessors at a central site. Upon completion of the 48-week crossover treatment period, subjects will receive their final dose of natalizumab 300 mg via their choice of SC or IV infusion route at week 156, proceed to a 12-week follow-up period, and complete the study after a follow-up safety call 12 weeks later (i.e., 24 weeks after the last dose of study treatment). The primary endpoint is the proportion of subjects who demonstrate a preference for SC administration of natalizumab at the end of the study period.

[0084] Secondary endpoints will be evaluated between 6 months of SC treatment and 6 months of IV treatment within the randomized crossover period and include satisfaction with the SC route of administration versus the IV route of administration, comparison of formulation and administration time between the SC and IV routes of natalizumab administration, evaluation of the safety and immunogenicity of the SC route of natalizumab versus the IV route of natalizumab administration, evaluation of the efficacy of the SC route of natalizumab versus the IV route of natalizumab administration, and analysis of the pharmacokinetics and pharmacodynamics of the SC route of natalizumab versus the IV route of natalizumab administration. Subjects who discontinue study treatment for any reason will be discontinued from the study and treated according to local standard of care.

[0085] All references, patents, and patent applications disclosed herein are incorporated by reference in their entirety for all purposes, specifically with respect to the subject matter for which each is cited, which in some cases may include entire documents.

Claims

1. 1. A composition for use in a method of reducing pathological inflammation in a patient in need thereof, comprising an anti-VLA-4 antibody, said method comprising administering a therapeutically effective amount of said composition to said patient in a two-phase dosing regimen, said two-phase regimen comprising an induction phase comprising administration of said composition once per month for 10-14 months, preferably at least 12 months, followed by a chronic phase comprising administration of said composition once every 5, 6, 7, or 8 weeks, preferably at least one phase of said two-phase protocol comprising subcutaneous (SC) administration.

2. 1. A composition for use in a method of reducing progressive multifocal leukoencephalopathy (PML) in a patient known or suspected to have multiple sclerosis, comprising an anti-VLA-4 antibody, said method comprising administering a therapeutically effective amount of said composition to said patient in a two-phase dosing regimen, said two-phase regimen comprising an induction phase comprising administration of said composition once a month for 10-14 months, preferably at least 12 months, followed by a chronic phase comprising administration of said composition once every 5, 6, 7, or 8 weeks, preferably at least one phase of said two-phase protocol comprising subcutaneous (SC) administration.

3. 2. The composition of claim 1, wherein the pathological inflammation is caused by multiple sclerosis and the therapeutically effective amount is sufficient to alleviate a symptom of multiple sclerosis.

4. The composition of any one of claims 1 to 3, wherein the anti-VLA-4 antibody is natalizumab.

5. The composition according to any one of claims 1 to 4, wherein the administration during the induction phase is intravenous (IV) or subcutaneous (SC), preferably SC.

6. The composition according to any one of claims 1 to 5, wherein the administration during the chronic phase is IV or SC, preferably SC.

7. The composition of any one of claims 1 to 6, wherein both phases of the regimen comprise SC administration.

8. The composition of any one of claims 1 to 7, wherein the therapeutically effective amount administered during the induction phase and the chronic phase is the same, preferably the therapeutically effective amount is 300 mg.

9. 8. The composition of any one of claims 1 to 7, wherein the therapeutically effective amount administered SC during the chronic phase is about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg, more preferably about 300 mg, even more preferably 300 mg.

10. A composition comprising natalizumab for use in a method of administering natalizumab to a patient in need of natalizumab based on a two-phase administration regimen, the method comprising administering the composition subcutaneously on a SID schedule over an induction phase of at least 12 months, followed by chronic administration of the composition on an EID schedule with intervals of at least 6 weeks between each administration, wherein one or both, preferably both, treatment phases comprise SC administration.

11. 11. The composition of claim 10, wherein the therapeutically effective amount administered during the induction phase and the chronic phase is the same, preferably the therapeutically effective amount is 300 mg.

12. 10. The composition of claim 9, wherein the therapeutically effective amount administered SC during the chronic phase is about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg, more preferably about 300 mg, even more preferably 300 mg.

13. The composition of any one of claims 1 to 12, wherein the method further comprises: a) measuring a soluble molecule in a first biological sample obtained from the patient during the induction phase, wherein the soluble molecule is serum vascular cell adhesion molecule (sVCAM) and / or neurofilament light chain (Nf-L); b) measuring sVCAM and / or Nf-L in a second biological sample obtained from the individual during the chronic phase; c) determining whether there is an increase in the levels of sVCAM and / or Nf-L above a predetermined level between the first and second biological samples; and d) if there is an increase above the predetermined level, returning the patient to a SID schedule or increasing the frequency of administration of the EID schedule.

14. A method for obtaining levels of sVCAM and / or Nf-L as an indicator for determining and / or monitoring the effectiveness of a two-phase administration protocol of natalizumab in a patient in need of determining and / or monitoring the effectiveness of the two-phase administration protocol, the two-phase administration protocol having an induction phase comprising a SID schedule and a chronic phase comprising an EID schedule, the method comprising: a) measuring soluble molecules in a first biological sample obtained from the patient during the induction phase, the soluble molecules being sVCAM and / or Nf-L; b) measuring sVCAM and / or Nf-L in a second biological sample obtained from the individual during the chronic phase; and c) determining whether there is an increase in the levels of sVCAM and / or Nf-L between the first sample and the second sample above a predetermined threshold, wherein an increase above one or both predetermined thresholds indicates that the patient should be returned to a SID schedule or the administration frequency of the EID schedule should be increased.